...and another hundred posts which takes
me up through the first week of February.
(That is where the thread got into the
debate about the details of the convertible.)
This kinda gives you the mood on the thread
through the January blip, and the beginning
of the realization that the stock would be
held down by this toxic deal. I cant give a
good explanation of what triggered me to post
some blurbs and not others--but since I got
one positive response, why not:
___
I can't understand why reputable companies like
this don't do a rights offering instead. That
way at least only shareholders that don't put
up money get diluted.
It's hard to disentangle the effects of these
financings from the sort of companies that do them.
I don't understand issuing $5mm in floorless cv
instead of drawing on the credit extended.
Gene Medicine's "Gene Switch" technology sounds very
similar to ARGENT
Just saw a talk by David Baltimore....showed some
experiments using Ariad's Dimerization Technology
....very impressive!
ARIAD announces Key Patent on Genes involved in Immune
Response and Cardiac Hypertrophy
"Our strong intellectual property position in NF-ATc
should be of great interest to any company engaged in
this area of drug discovery, especially those focused
on autoimmune and cardiac diseases."
This is a blatant advertisement and suggests that they
don't have anyone interested in partnering with them for
this program. When companies start advertising like this,
it is a very bad sign.
An abstract worth reading
Message 6744521
Wednesday December 9, 8:38 am Eastern Time
Company Press Release
ARIAD Initiates Phase 1 Human Clinical Trial On
Gene Regulation Drug to Treat Graft-versus-Host Disease
First Clinical Study of ARGENT(TM) Product
ARIA is most advanced at control of both "effector" function
and its elimination through apoptosis.
(here is where I cut my losses--too bad the January run up followed
--mm)
Message 7059797
A mixture of two adeno-associated virus vectors, one expressing
the transcription factor chimeras and one containing erythropoietin
(Epo) under the control of a promoter responsive to the transcription
factor, was injected into skeletal muscle of immune-competent mice.
Administration of rapamycin resulted in 200-fold induction of plasma
Epo. Stable engraftment of this humanized system in immune-competent
mice was achieved for 6 months with similar results for at least 3
months in a rhesus monkey.
Message 7060620
I agree that ARIA made a significant step forward. However, I think that the price and volume jump was largely driven by the WSJ article. Papers come out in Nature and Science weekly, but few cause a price
double at the open. A strong article in the popular press is usually
required.
The Financial Times of London covered the Science paper yesterday.
If you actually read patents, you'll get one heck of an education. Most of it will be irrelevant to what you are trying to do, however.
The current issue of Genetic Engineering News reviews vectors and
mentions the ARIA/Genova deal
Ariad is the only one that owes me, ha ha, and I'm going to ride
it for awhile.
When we started this thread, we used to discuss signal intervention, and ARGENT was this great project on the side.
Pangea Systems Inc. announced that its computational tools are
being used by Hoechst Marion Roussel and the Hoechst-ARIAD
Genomics Center to efficiently and accurately design custom
gene expression chips from full length gene sequences and
clustered gene fragments
the overhang and the sale of these shares should restrain any
major upward momentum. ARIA may be held down for quite a while
as the "investors" unload their cheap shares. |
